Reckitt announces U.S. investment. Reckitt Benckiser stock costs EUR 58.27 versus EUR 58.26
Published on 10/03/2026 at 10:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On September 16, 2026, Reckitt announced up to USD 600 million for a multi-year transformation of its U.S. operations across two sites in a company press release. Lang & Schwarz quoted Reckitt Benckiser at EUR 58.27 at 10:34 a.m. CEST on October 3, 2026, up 0.02 percent versus the close of EUR 58.26 at Lang & Schwarz on October 2, 2026.
Weekend trading at Lang & Schwarz
The quoted bid was EUR 58.08 and the ask was EUR 58.46. The price was EUR 0.01 above the close of EUR 58.26 at Lang & Schwarz on October 2, 2026. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CEST is shown by the continuously updated real-time quote of Reckitt Benckiser stock.
U.S. operations investment
Reckitt said the investment will bring its commercial and research and development capabilities together at a New Jersey campus and expand its over-the-counter manufacturing facility in North Carolina. The company said it had doubled the initial investment for the North Carolina facility, which is intended to become its largest over-the-counter manufacturing site in the United States. Additional funding is planned for Mucinex tablets and liquids and for higher production volumes of Move Free. The site is expected to open in the first half of 2027, according to the Reckitt announcement.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026.
